

Ravi Salgia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2223928/publications.pdf>

Version: 2024-02-01

400
papers

33,027
citations

4960

84
h-index

4991

167
g-index

415
all docs

415
docs citations

415
times ranked

34398
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic disorder, extraterrestrial peptides, and prebiotic life on the earth. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5481-5485.	3.5	2
2	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. <i>Seminars in Cancer Biology</i> , 2022, 83, 57-76.	9.6	33
3	MicroRNA-1: Diverse role of a small player in multiple cancers. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 114-126.	5.0	14
4	Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity. <i>International Journal of Biological Macromolecules</i> , 2022, 201, 29-36.	7.5	7
5	Abstract PO-009: Assessment of geographic and racial/ethnic variables in tobacco use among cancer patients in a widely dispersed academic-led cancer care network. , 2022, , .		0
6	Abstract PO-011: Use of clinician and nurse tobacco cessation champions to implement a tobacco control program in a geographically disseminated academic center-led clinical network analyzed by patient racial/ethnic group. , 2022, , .		0
7	Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. <i>Journal of Thoracic Oncology</i> , 2022, 17, 194-196.	1.1	8
8	Intrinsically Disordered Proteins: Critical Components of the Wetware. <i>Chemical Reviews</i> , 2022, 122, 6614-6633.	47.7	48
9	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1429.	2.4	12
10	Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma. <i>Biophysics Reviews</i> , 2022, 3, .	2.7	15
11	Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. <i>Biomolecules</i> , 2022, 12, 8.	4.0	13
12	Infectious complications of immune checkpoint inhibitors in solid organ malignancies. <i>Cancer Medicine</i> , 2022, 11, 21-27.	2.8	15
13	AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. <i>BMC Cancer</i> , 2022, 22, 447.	2.6	4
14	Leveraging deep learning algorithms for synthetic data generation to design and analyze biological networks. <i>Journal of Biosciences</i> , 2022, 47, .	1.1	12
15	Targeting RLIP with CRISPR/Cas9 controls tumor growth. <i>Carcinogenesis</i> , 2021, 42, 48-57.	2.8	15
16	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
17	Progressive Neurologic Changes in a Patient With Metastatic Non-“Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?. <i>JCO Oncology Practice</i> , 2021, 17, 52-53.	2.9	0
18	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. <i>Clinical Colorectal Cancer</i> , 2021, 20, e129-e138.	2.3	2

#	ARTICLE	IF	CITATIONS
19	JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i> -Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100103.	1.1	8
20	The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2021, 22, e84-e97.	2.6	19
21	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). <i>Cell Reports Medicine</i> , 2021, 2, 100186.	6.5	90
22	Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 188.	2.4	14
23	Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. <i>Molecular Carcinogenesis</i> , 2021, 60, 213-223.	2.7	2
24	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
25	RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. <i>Carcinogenesis</i> , 2021, 42, 742-752.	2.8	2
26	Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 621088.	2.8	23
27	RNA-based therapies: A cog in the wheel of lung cancer defense. <i>Molecular Cancer</i> , 2021, 20, 54.	19.2	53
28	Disparate outcomes in nonsmall cell lung cancer by immigration status. <i>Cancer Medicine</i> , 2021, 10, 2660-2667.	2.8	3
29	Quantifying Cancer: More Than Just a Numbers Game. <i>Trends in Cancer</i> , 2021, 7, 267-269.	7.4	4
30	Germline mutations and age at onset of lung adenocarcinoma. <i>Cancer</i> , 2021, 127, 2801-2806.	4.1	14
31	Group Behavior and Emergence of Cancer Drug Resistance. <i>Trends in Cancer</i> , 2021, 7, 323-334.	7.4	21
32	Activating p53 function by targeting RLIP. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188512.	7.4	2
33	ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?. <i>JCO Precision Oncology</i> , 2021, 5, 767-770.	3.0	6
34	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. <i>Nature Communications</i> , 2021, 12, 3039.	12.8	24
35	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
36	ST6GalNAc promotes lung cancer metastasis by altering MUC5AC sialylation. <i>Molecular Oncology</i> , 2021, 15, 1866-1881.	4.6	14

#	ARTICLE	IF	CITATIONS
37	The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β -Like 1- β -Catenin Protein Complex. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 77-86.	2.5	5
38	Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic. <i>Kidney Cancer</i> , 2021, 5, 73-78.	0.4	1
39	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
40	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
41	The Association between Polluted Neighborhoods and β -TP53-Mutated Non-Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1498-1505.	2.5	8
42	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). <i>British Journal of Cancer</i> , 2021, 125, 582-592.	6.4	4
43	Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	2
44	Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. <i>Cancers</i> , 2021, 13, 3407.	3.7	4
45	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1820-1835.	4.1	9
46	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16266.	0.5	4
47	Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. <i>Oncologist</i> , 2021, 26, 1052-1061.	3.7	50
48	Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment. <i>Cancers</i> , 2021, 13, 4265.	3.7	7
49	Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. <i>JCO Oncology Practice</i> , 2021, 17, e1120-e1130.	2.9	8
50	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. <i>Chest</i> , 2021, 160, 1095-1107.	0.8	23
51	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. <i>Clinical Lung Cancer</i> , 2021, 22, e703-e707.	2.6	5
52	Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e678-e683.	2.6	3
53	Targeting the mercapturic acid pathway for the treatment of melanoma. <i>Cancer Letters</i> , 2021, 518, 10-22.	7.2	5
54	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). <i>Cancers</i> , 2021, 13, 7.	3.7	13

#	ARTICLE	IF	CITATIONS
55	Response. Chest, 2021, 160, e375-e376.	0.8	0
56	Protein conformational dynamics and phenotypic switching. Biophysical Reviews, 2021, 13, 1127-1138.	3.2	9
57	Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma. Frontiers in Pharmacology, 2021, 12, 806570.	3.5	4
58	The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine, 2020, 26, 119-134.	6.7	121
59	SOX9: The master regulator of cell fate in breast cancer. Biochemical Pharmacology, 2020, 174, 113789.	4.4	47
60	Presence and structure-activity relationship of intrinsically disordered regions across mucins. FASEB Journal, 2020, 34, 1939-1957.	0.5	7
61	RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188337.	7.4	6
62	Integrating Clinical and Translational Research Networks—Building Team Medicine. Journal of Clinical Medicine, 2020, 9, 2975.	2.4	5
63	Phenotypic switching and prostate diseases: a model proposing a causal link between benign prostatic hyperplasia and prostate cancer. , 2020, , 569-589.		0
64	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. IScience, 2020, 23, 101692.	4.1	9
65	A Non-genetic Mechanism Involving the Integrin β 4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. IScience, 2020, 23, 101496.	4.1	27
66	Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Journal of Clinical Medicine, 2020, 9, 2433.	2.4	9
67	Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. Journal of Biological Chemistry, 2020, 295, 13393-13406.	3.4	12
68	Expanding the Definition of Oligometastatic in Lung Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, E50-E51.	0.8	0
69	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines, 2020, 8, 617.	3.2	14
70	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers, 2020, 12, 3851.	3.7	27
71	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. Journal of Thoracic Disease, 2020, 12, 5096-5103.	1.4	0
72	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. Journal of Thoracic Disease, 2020, 12, 5086-5095.	1.4	29

#	ARTICLE	IF	CITATIONS
73	Therapeutic targeting of miRNA-216b in cancer. <i>Cancer Letters</i> , 2020, 484, 16-28.	7.2	12
74	Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. <i>Frontiers in Oncology</i> , 2020, 10, 593.	2.8	25
75	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1870.	2.4	16
76	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
77	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	16.8	389
78	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. <i>Magnetic Resonance Imaging</i> , 2020, 69, 49-56.	1.8	34
79	Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. <i>Journal of Clinical Medicine</i> , 2020, 9, 1820.	2.4	7
80	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884.	2.4	5
81	MET receptor in oncology: From biomarker to therapeutic target. <i>Advances in Cancer Research</i> , 2020, 147, 259-301.	5.0	20
82	Association of TGF- β 1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies. <i>Cancers</i> , 2020, 12, 471.	3.7	5
83	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. <i>Future Oncology</i> , 2020, 16, 4289-4301.	2.4	12
84	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
85	The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. <i>Cancer Treatment Reviews</i> , 2020, 87, 102022.	7.7	51
86	Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1210-1217.	4.1	17
87	USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. <i>Molecular Cancer Research</i> , 2020, 18, 424-435.	3.4	12
88	Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005785.	1.2	8
89	AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4349-4359.	7.0	26
90	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9080-TPS9080.	1.6	5

#	ARTICLE	IF	CITATIONS
91	The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. <i>Oncotarget</i> , 2020, 11, 1953-1960.	1.8	19
92	Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. <i>International Journal of Oncology</i> , 2020, 57, 80-86.	3.3	1
93	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
94	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
95	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
96	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
97	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	1.1	8
98	Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. <i>Journal of Clinical Medicine</i> , 2019, 8, 1038.	2.4	8
99	Notch signaling in breast cancer: From pathway analysis to therapy. <i>Cancer Letters</i> , 2019, 461, 123-131.	7.2	69
100	Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1632-1640.	2.0	8
101	The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. <i>Clinical and Translational Medicine</i> , 2019, 8, 9.	4.0	80
102	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee “ International Association for the Study of Lung Cancer “ Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731.	1.1	15
103	Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 1723.	2.4	5
104	Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. <i>Journal of Clinical Medicine</i> , 2019, 8, 1726.	2.4	26
105	EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. <i>Oncogenesis</i> , 2019, 8, 49.	4.9	17
106	RLIP inhibition suppresses breast-to-lung metastasis. <i>Cancer Letters</i> , 2019, 447, 24-32.	7.2	16
107	Targeted Therapies in Non-small-Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 3-43.	0.5	16
108	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. <i>Lung Cancer</i> , 2019, 133, 136-143.	2.0	21

#	ARTICLE	IF	CITATIONS
109	Synergistic efficacy of RLIP inhibition and 2â€²â€²hydroxyflavanone against DMBAâ€²induced mammary carcinogenesis in SENCAR mice. <i>Molecular Carcinogenesis</i> , 2019, 58, 1438-1449.	2.7	13
110	Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. <i>Biomolecules</i> , 2019, 9, 77.	4.0	19
111	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 1-6.	4.4	26
112	Early mortality of stage IV non-small cell lung cancer in the United States. <i>Acta OncolÃ³gica</i> , 2019, 58, 1095-1101.	1.8	8
113	RLIP: An existential requirement for breast carcinogenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 281-288.	7.4	9
114	Anaplastic Lymphoma Kinase (ALK)-positive Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 337-344.	1.3	6
115	Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. <i>Cell Communication and Signaling</i> , 2019, 17, 167.	6.5	36
116	Opportunities for improving cancer treatment using systems biology. <i>Current Opinion in Systems Biology</i> , 2019, 17, 41-50.	2.6	5
117	The DNA walk and its demonstration of deterministic chaosâ€²relevance to genomic alterations in lung cancer. <i>Bioinformatics</i> , 2019, 35, 2738-2748.	4.1	8
118	2â€²-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. <i>Journal of Proteomics</i> , 2019, 192, 233-245.	2.4	10
119	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8577-TPS8577.	1.6	11
120	MET as a Therapeutic Target: Have Clinical Outcomes Been â€œMETâ€²in Lung Cancer?. <i>Current Cancer Research</i> , 2019, , 101-123.	0.2	0
121	Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9093-9093.	1.6	2
122	Lung cancer in African-Americans and analysis of estrogen plus progestin use.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18258-e18258.	1.6	0
123	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1897-1908.	2.4	5
124	EphB4: A promising target for upper aerodigestive malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 128-137.	7.4	16
125	The Genetic/Non-genetic Duality of Drug â€²Resistanceâ€²™ in Cancer. <i>Trends in Cancer</i> , 2018, 4, 110-118.	7.4	201
126	Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. <i>Cancer Biology and Therapy</i> , 2018, 19, 316-327.	3.4	86

#	ARTICLE	IF	CITATIONS
127	Untying the gordian knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 95-103.	7.7	18
128	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. <i>Cell</i> , 2018, 173, 470-484.e18.	28.9	89
129	Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 963-966.	1.3	5
130	Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 569-571.	2.5	5
131	Managing Patients With Relapsed Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 359-366.	2.5	38
132	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32.	4.0	29
133	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. <i>Journal of Clinical Medicine</i> , 2018, 7, 156.	2.4	10
134	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
135	Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. <i>Cancer Biology and Therapy</i> , 2018, 19, 1023-1032.	3.4	12
136	Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. <i>Oncotarget</i> , 2018, 9, 26226-26242.	1.8	14
137	Value-based genomics. <i>Oncotarget</i> , 2018, 9, 15792-15815.	1.8	46
138	Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2-Hydroxyflavanone. <i>Cancer Letters</i> , 2018, 438, 144-153.	7.2	13
139	Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. <i>Seminars in Oncology</i> , 2018, 45, 210-219.	2.2	48
140	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 309-317.	2.3	12
141	Effective osimertinib treatment in a patient with discordant T790M mutation detection between liquid biopsy and tissue biopsy. <i>BMC Cancer</i> , 2018, 18, 314.	2.6	6
142	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
143	2-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. <i>Molecular Carcinogenesis</i> , 2018, 57, 1751-1762.	2.7	22
144	Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 124-128.	1.9	52

#	ARTICLE	IF	CITATIONS
145	2â€™-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. <i>Oncotarget</i> , 2018, 9, 18053-18068.	1.8	21
146	Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 19793-19806.	1.8	34
147	Heuristic value-based framework for lung cancer decision-making. <i>Oncotarget</i> , 2018, 9, 29877-29891.	1.8	5
148	Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Nonâ€“Small Cell Lung Cancer Treatment Setting. <i>Journal of Clinical Pathways: the Foundation of Value-based Care</i> , 2018, 4, 49-54.	0.2	15
149	Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Nonâ€“small Cell Lung Cancer and Malignant Mesothelioma. <i>FASEB Journal</i> , 2018, 32, 835.9.	0.5	0
150	A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensiveâ€“disease small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 7-13.	2.0	49
151	Loss of H2B monoubiquitination is associated with poorâ€“differentiation and enhanced malignancy of lung adenocarcinoma. <i>International Journal of Cancer</i> , 2017, 141, 766-777.	5.1	27
152	Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. <i>Oncology Letters</i> , 2017, 13, 4027-4034.	1.8	4
153	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. <i>Cancer Treatment Reviews</i> , 2017, 55, 181-189.	7.7	12
154	<sc>TOPK</sc> (Tâ€“<sc>LAK</sc> cellâ€“originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 488-496.	3.9	28
155	MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 555-565.	4.1	129
156	Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. <i>Investigational New Drugs</i> , 2017, 35, 334-344.	2.6	32
157	Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. <i>Scientific Reports</i> , 2017, 7, 9192.	3.3	13
158	Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. <i>European Journal of Oncology Nursing</i> , 2017, 29, 125-134.	2.1	39
159	Synergistic Anti-Cancer Effect of Baicalein and Metformin against Human Lung Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 225, S35-S36.	0.5	0
160	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. <i>Oncotarget</i> , 2017, 8, 67639-67650.	1.8	26
161	Value-Based Medicine and Integration of Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 833-840.	3.8	7
162	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. <i>Oncotarget</i> , 2017, 8, 42198-42213.	1.8	49

#	ARTICLE	IF	CITATIONS
163	Value-Based Medicine and Integration of Tumor Biology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 833-840.	3.8	2
164	Genomic mutation-driven metastatic breast cancer therapy: a single center experience. <i>Oncotarget</i> , 2017, 8, 26414-26423.	1.8	12
165	Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. <i>Oncotarget</i> , 2017, 8, 43733-43751.	1.8	20
166	State-of-the-art considerations in small cell lung cancer brain metastases. <i>Oncotarget</i> , 2017, 8, 71223-71233.	1.8	47
167	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 18726-18734.	1.8	6
168	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. <i>Oncotarget</i> , 2016, 7, 66880-66891.	1.8	54
169	Tumor Heterogeneity and Therapeutic Resistance. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e585-e593.	3.8	30
170	Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 568.	2.6	1
171	Prognostic and Predictive Value in <i>KRAS</i> in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 805.	7.1	126
172	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 737-749.	3.1	24
173	MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1381-1383.	1.1	7
174	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. <i>Cancer Letters</i> , 2016, 380, 494-504.	7.2	137
175	Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2175-2186.	4.1	36
176	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. <i>Scientific Reports</i> , 2016, 6, 24578.	3.3	32
177	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1683-1696.	10.7	298
178	PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. <i>Scientific Reports</i> , 2016, 6, 32992.	3.3	24
179	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	3.7	119
180	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. <i>Future Oncology</i> , 2016, 12, 1045-1058.	2.4	10

#	ARTICLE	IF	CITATIONS
181	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
182	<i>C. elegans</i> and mutants with chronic nicotine exposure as a novel model of cancer phenotype. <i>Cancer Biology and Therapy</i> , 2016, 17, 91-103.	3.4	3
183	Tumor Heterogeneity and Therapeutic Resistance. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e585-e593.	3.8	12
184	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 13621-13633.	1.8	41
185	Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. <i>Oncotarget</i> , 2016, 7, 18876-18886.	1.8	25
186	FAK and paxillin, two potential targets in pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 31586-31601.	1.8	88
187	Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. <i>Cureus</i> , 2016, 8, e513.	0.5	21
188	Role Played by Paxillin and Paxillin Tyrosine Phosphorylation in Hepatocyte Growth Factor/Sphingosine-1-Phosphate-Mediated Reactive Oxygen Species Generation, Lamellipodia Formation, and Endothelial Barrier Function. <i>Pulmonary Circulation</i> , 2015, 5, 619-630.	1.7	21
189	Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 10641.	3.3	17
190	Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 442-447.	1.3	7
191	HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. <i>Frontiers in Oncology</i> , 2015, 5, 164.	2.8	26
192	Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 850-859.	9.4	632
193	c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L1025-L1038.	2.9	29
194	A new PET/CT volumetric prognostic index for non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 43-49.	2.0	19
195	Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-small Cell Lung Cancer Who Previously Progressed on Erlotinib. <i>Clinical Cancer Research</i> , 2015, 21, 4321-4326.	7.0	59
196	Lung cancer—a fractal viewpoint. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 664-675.	27.6	129
197	Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin. <i>Journal of Molecular Biology</i> , 2015, 427, 2532-2547.	4.2	9
198	A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 485-493.	2.4	13

#	ARTICLE	IF	CITATIONS
199	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2601-2612.	7.0	94
200	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	1.1	119
201	A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 461-469.	4.1	28
202	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4284-4292.	1.6	431
203	Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. <i>Future Oncology</i> , 2015, 11, 489-500.	2.4	20
204	PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. <i>Journal of Biological Chemistry</i> , 2015, 290, 21901-21914.	3.4	20
205	ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1978-1979.	1.5	6
206	Whole-animal mounts of <i>Caenorhabditis elegans</i> for 3D imaging using atomic force microscopy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1971-1974.	3.3	11
207	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. <i>Clinical Cancer Research</i> , 2015, 21, 870-881.	7.0	303
208	Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC). <i>Journal of Clinical Oncology</i> , 2015, 33, 7567-7567.	1.6	1
209	Activating the Expression of Human K-rasG12D Stimulates Oncogenic Transformation in Transgenic Goat Fetal Fibroblast Cells. <i>PLoS ONE</i> , 2014, 9, e90059.	2.5	3
210	The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e91577.	2.5	165
211	Molecular pathways and therapeutic targets in lung cancer. <i>Oncotarget</i> , 2014, 5, 1392-1433.	1.8	171
212	Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. <i>Case Reports in Clinical Pathology</i> , 2014, 1, 151-154.	0.0	10
213	Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. <i>CNS Oncology</i> , 2014, 3, 61-75.	3.0	9
214	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 1666-1675.	7.0	61
215	Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies and implications for solid tumors and potential for therapeutic inhibition. <i>Growth Factors</i> , 2014, 32, 202-206.	1.7	13
216	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. <i>Advances in Experimental Medicine and Biology</i> , 2014, 799, 85-117.	1.6	98

#	ARTICLE	IF	CITATIONS
217	Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. <i>Cancer Medicine</i> , 2014, 3, 681-692.	2.8	23
218	Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 185.	2.6	15
219	Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 6336-6345.	7.0	70
220	Geographic Variation in Radiologist Capacity and Widespread Implementation of Lung Cancer CT Screening. <i>Journal of Medical Screening</i> , 2014, 21, 207-215.	2.3	21
221	Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 576-584.	4.1	19
222	Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. <i>Cancer Letters</i> , 2014, 343, 14-23.	7.2	22
223	Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 13476-13491.	3.4	73
224	Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1963-1971.	27.0	1,656
225	Transactivation of the Receptor-tyrosine Kinase Ephrin Receptor A2 Is Required for the Low Molecular Weight Hyaluronan-mediated Angiogenesis That Is implicated in Tumor Progression. <i>Journal of Biological Chemistry</i> , 2014, 289, 24043-24058.	3.4	33
226	Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1356-1368.	4.1	53
227	Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2328-2334.	1.6	121
228	AXL Mediates Resistance to Cetuximab Therapy. <i>Cancer Research</i> , 2014, 74, 5152-5164.	0.9	170
229	Mitochondrial dynamics: biology and therapy in lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 675-692.	4.1	35
230	Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 884-895.	0.9	55
231	MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2014, 9, e105919.	2.5	52
232	EphB4 as a therapeutic target in mesothelioma. <i>BMC Cancer</i> , 2013, 13, 269.	2.6	28
233	MET As a Possible Target for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1089-1096.	1.6	173
234	A New Hope for Precision Medicine. <i>Science Translational Medicine</i> , 2013, 5, 208fs38.	12.4	0

#	ARTICLE	IF	CITATIONS
235	Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in <i>MET</i> -Mutated Papillary Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e254-e258.	1.6	29
236	Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers. <i>Cancer Research</i> , 2013, 73, 184-194.	0.9	48
237	Critical Role of S1PR1 and Integrin α 4 in HGF/c-Met-mediated Increases in Vascular Integrity. <i>Journal of Biological Chemistry</i> , 2013, 288, 2191-2200.	3.4	38
238	A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3068-3077.	7.0	212
239	Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics. <i>Cancer Biology and Therapy</i> , 2013, 14, 679-691.	3.4	36
240	The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target. <i>PLoS ONE</i> , 2013, 8, e67668.	2.5	56
241	Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases. <i>Tumori</i> , 2013, 99, e73-e76.	1.1	1
242	Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis. <i>International Journal of Medical Sciences</i> , 2013, 10, 988-994.	2.5	22
243	CD14+S100A9+Myeloid-derived Suppressor Cells Portend Decreased Survival in Patients with Advanced Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 940-941.	5.6	4
244	Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. <i>ImmunoTargets and Therapy</i> , 2012, 2012, 7.	5.8	25
245	Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 376-381.	1.1	96
246	Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 856-865.	1.1	39
247	Three-Dimensional Stereoscopic Volume Rendering of Malignant Pleural Mesothelioma. <i>International Surgery</i> , 2012, 97, 65-70.	0.1	2
248	Inhibition of MET Receptor Tyrosine Kinase and Its Ligand Hepatocyte Growth Factor. <i>Journal of Thoracic Oncology</i> , 2012, 7, S372-S374.	1.1	6
249	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , 2012, 13, 1011-1019.	10.7	1,176
250	Quality of Life After Radical Pleurectomy Decortication for Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1086-1092.	1.3	40
251	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. <i>Targeted Oncology</i> , 2012, 7, 199-210.	3.6	28
252	A Novel Classification of Lung Cancer into Molecular Subtypes. <i>PLoS ONE</i> , 2012, 7, e31906.	2.5	99

#	ARTICLE	IF	CITATIONS
253	Differential expression of RON in small and non-small cell lung cancers. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 841-851.	2.8	32
254	Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. <i>FASEB Journal</i> , 2012, 26, 2175-2186.	0.5	458
255	Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-small-Cell Lung Cancer, A Phase II Trial. <i>Clinical Lung Cancer</i> , 2012, 13, 123-128.	2.6	10
256	Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 25-32.	0.8	109
257	The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 33-38.	0.8	554
258	Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. <i>Journal of Neurology Research</i> , 2012, 2, 1-9.	0.5	7
259	Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. <i>Journal of Clinical Bioinformatics</i> , 2011, 1, 8.	1.2	10
260	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1004-1012.	10.7	847
261	Role of MetMab (OA-5D5) in c-MET active lung malignancies. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1655-1662.	3.1	48
262	Inhibition of MET Receptor Tyrosine Kinase and Its Ligand Hepatocyte Growth Factor. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1810-S1811.	1.1	7
263	MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2011, 30, 341-354.	1.2	24
264	The Novel Role of the Mu Opioid Receptor in Lung Cancer Progression. <i>Anesthesia and Analgesia</i> , 2011, 112, 558-567.	2.2	230
265	Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1418-1425.	1.1	59
266	Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1741-1745.	1.1	10
267	Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	4
268	Personalized Treatment of Lung Cancer. <i>Seminars in Oncology</i> , 2011, 38, 274-283.	2.2	35
269	Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. <i>Cancer</i> , 2011, 117, 3889-3899.	4.1	49
270	An E3 ubiquitin ligase: c-Cbl. <i>Cancer</i> , 2011, 117, 5344-5350.	4.1	29

#	ARTICLE	IF	CITATIONS
271	RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2011, 12, 9-46.	3.4	79
272	Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2660-2666.	1.6	504
273	Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells. <i>Clinical Cancer Research</i> , 2011, 17, 3112-3122.	7.0	32
274	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2011, 6, 942-946.	1.1	407
275	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5257-5267.	7.0	75
276	Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. <i>Journal of Clinical Pathology</i> , 2011, 64, 16-24.	2.0	43
277	Takotsubo Cardiomyopathy in a Patient With Squamous Cell Esophageal Carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e598-e600.	1.6	7
278	Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non-Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions. <i>Cancer Research</i> , 2011, 71, 2423-2427.	0.9	44
279	Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 786-789.	1.1	16
280	MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. <i>Journal of Clinical Oncology</i> , 2011, 29, 4803-4810.	1.6	404
281	Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. <i>Cancer Discovery</i> , 2011, 1, 573-579.	9.4	105
282	The role of the c-Met pathway in lung cancer and the potential for targeted therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 171-184.	3.2	103
283	Crizotinib: ALK/Met inhibitor, oncolytic. <i>Drugs of the Future</i> , 2011, 36, 91.	0.1	13
284	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2044-2046.	1.1	73
285	CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases. <i>PLoS ONE</i> , 2010, 5, e8972.	2.5	98
286	EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation. <i>Journal of Biological Chemistry</i> , 2010, 285, 18575-18585.	3.4	97
287	Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1693-1703.	27.0	4,141
288	Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. <i>Journal of Biological Chemistry</i> , 2010, 285, 32596-32605.	3.4	42

#	ARTICLE	IF	CITATIONS
289	Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer. <i>Current Proteomics</i> , 2010, 7, 49-56.	0.3	23
290	MET molecular mechanisms and therapies in lung cancer. <i>Cell Adhesion and Migration</i> , 2010, 4, 146-152.	2.7	55
291	The role of chemokine receptor CXCR4 in lung cancer. <i>Cancer Biology and Therapy</i> , 2010, 9, 409-416.	3.4	59
292	Expression Patterns of PAX5, c-Met, and Paxillin in Neuroendocrine Tumors of the Lung. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1702-1705.	2.5	42
293	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2009, 69, 3021-3031.	0.9	236
294	The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2009, 14, 1116-1130.	3.7	57
295	PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene. <i>Journal of Biological Chemistry</i> , 2009, 284, 27524-27532.	3.4	43
296	Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2009, 69, 7538-7547.	0.9	83
297	Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5714-5723.	7.0	174
298	Role of c-Met in Cancer: Emphasis on Lung Cancer. <i>Seminars in Oncology</i> , 2009, 36, S52-S58.	2.2	49
299	PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. <i>Laboratory Investigation</i> , 2009, 89, 301-314.	3.7	98
300	<i>FYN</i> is overexpressed in human prostate cancer. <i>BJU International</i> , 2009, 103, 171-177.	2.5	79
301	The MET axis as a therapeutic target. <i>Update on Cancer Therapeutics</i> , 2009, 3, 109-118.	0.4	33
302	MET as a target for treatment of chest tumors. <i>Lung Cancer</i> , 2009, 63, 169-179.	2.0	117
303	MET Pathway as a Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2009, 4, 444-447.	1.1	61
304	MET, HGF, EGFR, and PXN Gene Copy Number in Lung Cancer Using DNA Extracts from FFPE Archival Samples and Prognostic Significance. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2009, 28, 89-98.	1.2	37
305	NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms.. <i>Blood</i> , 2009, 114, 2190-2190.	1.4	0
306	Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 549-558.	2.3	62

#	ARTICLE	IF	CITATIONS
307	Expression and mutational analysis of <i>MET</i> in human solid cancers. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1025-1037.	2.8	282
308	Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia. <i>Gynecologic Oncology</i> , 2008, 110, 49-55.	1.4	154
309	Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. <i>Journal of Carcinogenesis</i> , 2008, 7, 9.	2.5	183
310	<i>C. elegans</i> as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect <i>C. elegans</i> vulva phenotypes. <i>Cancer Biology and Therapy</i> , 2008, 7, 856-863.	3.4	30
311	Randomized Phase II Study of Carboplatin and Etoposide With or Without the <i>bcl-2</i> Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103. <i>Journal of Clinical Oncology</i> , 2008, 26, 870-876.	1.6	158
312	Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity. <i>Clinical Cancer Research</i> , 2008, 14, 3896-3905.	7.0	28
313	Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion. <i>Cancer Research</i> , 2008, 68, 132-142.	0.9	114
314	Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1003-1011.	1.1	64
315	Protein kinase C beta in malignant pleural mesothelioma. <i>Anti-Cancer Drugs</i> , 2008, 19, 841-848.	1.4	11
316	EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC. <i>Scientific World Journal</i> , The, 2008, 8, 909-919.	2.1	25
317	Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2948-2948.	1.4	2
318	Lymphatic Vessel Density Is Not Associated With Lymph Node Metastasis in Non-Small Cell Lung Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1882-1888.	2.5	18
319	c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion. <i>Cancer Research</i> , 2007, 67, 1670-1679.	0.9	239
320	Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L1488-L1494.	2.9	50
321	Tyrosine Kinase Mutations in Human Cancer. <i>Current Molecular Medicine</i> , 2007, 7, 77-84.	1.3	63
322	Lung carcinoma in African Americans. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 118-129.	4.3	47
323	A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts. <i>Cancer Research</i> , 2007, 67, 3529-3534.	0.9	119
324	A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 515-522.	7.0	84

#	ARTICLE	IF	CITATIONS
325	CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity. <i>Journal of Biological Chemistry</i> , 2007, 282, 30643-30657.	3.4	109
326	Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 258-263.	1.3	9
327	Review of Clinic Trials: Agents Targeting c-Met. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 143-147.	0.8	27
328	c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 2246-2253.	7.0	152
329	P1-132: Phase II study of erlotinib plus bevacizumab in patients with previously treated malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007, 2, S602.	1.1	0
330	Biomarker discovery in lung cancerâ€™ promises and challenges of clinical proteomics. <i>Mass Spectrometry Reviews</i> , 2007, 26, 451-466.	5.4	58
331	Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC Î´ and E-cadherin. <i>Cellular Signalling</i> , 2007, 19, 2329-2338.	3.6	29
332	c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy. <i>Current Oncology Reports</i> , 2007, 9, 102-108.	4.0	119
333	A5-06: Heat shock protein 27 - a novel target for non-small cell lung cancer and possible marker of metastasis. <i>Journal of Thoracic Oncology</i> , 2007, 2, S325.	1.1	0
334	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. <i>Respirology</i> , 2006, 11, 687-692.	2.3	32
335	A review of topoisomerase inhibition in lung cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 1600-1607.	3.4	32
336	Epidermal Growth Factor Receptorâ€™ Mediated Signal Transduction in the Development and Therapy of Gliomas. <i>Clinical Cancer Research</i> , 2006, 12, 7261-7270.	7.0	193
337	Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma. <i>Cancer Research</i> , 2006, 66, 352-361.	0.9	185
338	Gefitinib response of erlotinib-refractory lung cancer involving meningesâ€™ role of EGFR mutation. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 50-57.	4.3	114
339	c-Met inhibition. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 823-4.	0.3	4
340	A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin. <i>Clinical Cancer Research</i> , 2005, 11, 2312-2319.	7.0	121
341	Expression of Siva-1 Protein or Its Putative Amphipathic Helical Region Enhances Cisplatin-Induced Apoptosis in Breast Cancer Cells: Effect of Elevated Levels of BCL-2. <i>Cancer Research</i> , 2005, 65, 5301-5309.	0.9	90
342	Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. <i>Blood</i> , 2005, 105, 1717-1723.	1.4	208

#	ARTICLE	IF	CITATIONS
343	Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Nonâ€“Small Cell Lung Cancer. <i>Cancer Research</i> , 2005, 65, 1479-1488.	0.9	530
344	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. <i>Cancer Letters</i> , 2005, 225, 1-26.	7.2	488
345	Receptor Tyrosine Kinases and Inhibitors in Lung Cancer. <i>Scientific World Journal</i> , The, 2004, 4, 589-604.	2.1	42
346	Reliable and Sensitive Identification of Occult Tumor Cells Using the Improved Rare Event Imaging System. <i>Clinical Cancer Research</i> , 2004, 10, 3020-3028.	7.0	56
347	The role of ephrins and Eph receptors in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2004, 15, 419-433.	7.2	307
348	Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell line, Calu-1. <i>Annals of Thoracic Surgery</i> , 2004, 78, 450-457.	1.3	17
349	Novel Targets for Therapeutic Agents in Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 165-172.	4.9	6
350	Therapeutic Targeting of the Receptor Tyrosine Kinase Met. , 2004, 119, 121-138.		17
351	Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. <i>Anticancer Research</i> , 2004, 24, 1031-8.	1.1	73
352	c-Met: structure, functions and potential for therapeutic inhibition. <i>Cancer and Metastasis Reviews</i> , 2003, 22, 309-325.	5.9	447
353	Benefit of Active Treatment in Nonâ€“Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status. <i>Clinical Lung Cancer</i> , 2003, 5, 86-89.	2.6	4
354	Molecular and cellular biology of small cell lung cancer. <i>Seminars in Oncology</i> , 2003, 30, 57-71.	2.2	65
355	Small cell lung cancer: from molecular biology to novel therapeutics. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003, 3, 305-318.	0.5	14
356	Use of Temozolomide with Other Cytotoxic Chemotherapy in the Treatment of Patients with Recurrent Brain Metastases from Lung Cancer. <i>Oncologist</i> , 2003, 8, 69-75.	3.7	50
357	Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Nonâ€“Small-Cell Lung Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 624-630.	1.6	268
358	Small-Cell Cancers, and an Unusual Reaction to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2437-2438.	1.6	12
359	2-Methoxyestradiol alters cell motility, migration, and adhesion. <i>Blood</i> , 2003, 102, 289-296.	1.4	41
360	Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. <i>Anticancer Research</i> , 2003, 23, 49-62.	1.1	28

#	ARTICLE	IF	CITATIONS
361	Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. <i>Anticancer Research</i> , 2003, 23, 3379-96.	1.1	15
362	A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. <i>Cancer Research</i> , 2003, 63, 5462-9.	0.9	189
363	c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. <i>Cancer Research</i> , 2003, 63, 6272-81.	0.9	369
364	p53 and Bcl-2 in small cell-lung cancer. <i>Clinical Lung Cancer</i> , 2003, 4, 303.	2.6	0
365	Phase II study of imatinib in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5880-7.	7.0	145
366	Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β 1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKC δ Activation. <i>Journal of Biological Chemistry</i> , 2002, 277, 7875-7881.	3.4	161
367	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6919-6924.	7.1	45
368	CD2 molecules redistribute to the uropod during T cell scanning: Implications for cellular activation and immune surveillance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7582-7587.	7.1	46
369	A Fragment of Paxillin Binds the β 4 Integrin Cytoplasmic Domain (Tail) and Selectively Inhibits β 4-Mediated Cell Migration. <i>Journal of Biological Chemistry</i> , 2002, 277, 20887-20894.	3.4	51
370	Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 41-59.	7.2	366
371	Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. <i>Oncogene</i> , 2002, 21, 1423-1433.	5.9	24
372	Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 620-7.	7.0	201
373	Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. <i>Cancer Research</i> , 2002, 62, 5242-7.	0.9	103
374	Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. <i>Cancer Research</i> , 2002, 62, 6304-11.	0.9	225
375	Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 151-159.	2.3	28
376	SHIP1, an SH2 Domain Containing Polyinositol-5-phosphatase, Regulates Migration through Two Critical Tyrosine Residues and Forms a Novel Signaling Complex with DOK1 and CRKL. <i>Journal of Biological Chemistry</i> , 2001, 276, 2451-2458.	3.4	50
377	Chemokine Receptors CXCR-1/2 Activate Mitogen-activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 6868-6875.	3.4	185
378	Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. <i>Oncogene</i> , 2000, 19, 3521-3528.	5.9	226

#	ARTICLE	IF	CITATIONS
379	Case 1: Small Bowel Obstruction Due to Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 227-227.	1.6	15
380	The Noncatalytic Domain of Protein-tyrosine Phosphatase-PEST Targets Paxillin for Dephosphorylation in Vivo. <i>Journal of Biological Chemistry</i> , 2000, 275, 1405-1413.	3.4	63
381	The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 24273-24278.	3.4	280
382	Molecular Cloning and Characterization of Human Trabeculin- β , a Giant Protein Defining a New Family of Actin-binding Proteins. <i>Journal of Biological Chemistry</i> , 1999, 274, 33522-33530.	3.4	39
383	The Role of Focal Adhesion Kinase Binding in the Regulation of Tyrosine Phosphorylation of Paxillin. <i>Journal of Biological Chemistry</i> , 1999, 274, 36684-36692.	3.4	126
384	Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. <i>Oncogene</i> , 1999, 18, 67-77.	5.9	83
385	Involvement of the adapter protein CRKL in integrin-mediated adhesion. <i>Oncogene</i> , 1999, 18, 3343-3353.	5.9	29
386	Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL. <i>Journal of Biological Chemistry</i> , 1997, 272, 10248-10253.	3.4	95
387	Involvement of p130Cas and p105HEF1, a Novel Cas-like Docking Protein, in a Cytoskeleton-dependent Signaling Pathway Initiated by Ligation of Integrin or Antigen Receptor on Human B Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 4230-4236.	3.4	106
388	The Bovine Papillomavirus E6 Protein Binds to the LD Motif Repeats of Paxillin and Blocks Its Interaction with Vinculin and the Focal Adhesion Kinase. <i>Journal of Biological Chemistry</i> , 1997, 272, 33373-33376.	3.4	82
389	Differential Signaling after β 1 Integrin Ligation Is Mediated Through Binding of CRKL to p120 and p110. <i>Journal of Biological Chemistry</i> , 1997, 272, 14320-14326.	3.4	89
390	Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. <i>Cytokine and Growth Factor Reviews</i> , 1997, 8, 63-79.	7.2	101
391	Association of the Cas-like Molecule HEF1 with CrkL Following Integrin and Antigen Receptor Signaling in Human B-Cells: Potential Relevance to Neoplastic Lymphohematopoietic Cells. <i>Leukemia and Lymphoma</i> , 1997, 28, 65-72.	1.3	40
392	The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. <i>Oncogene</i> , 1997, 15, 2379-2384.	5.9	73
393	Thrombopoietin induces activation of the phosphatidylinositol-3-kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. <i>Journal of Cellular Physiology</i> , 1997, 171, 28-33.	4.1	35
394	Role of Focal Adhesion Proteins in Signal Transduction and Oncogenesis. <i>Critical Reviews in Oncogenesis</i> , 1997, 8, 343-358.	0.4	62
395	The Related Adhesion Focal Tyrosine Kinase Forms a Complex with Paxillin in Hematopoietic Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 31222-31226.	3.4	129
396	p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene. <i>Journal of Biological Chemistry</i> , 1996, 271, 25198-25203.	3.4	109

#	ARTICLE	IF	CITATIONS
397	CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells. Journal of Biological Chemistry, 1995, 270, 29145-29150.	3.4	114
398	Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL. Journal of Biological Chemistry, 1995, 270, 5039-5047.	3.4	246
399	Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. Cancer, 1994, 74, 1887-1890.	4.1	8
400	Altered membrane fluidity in rat hepatocytes during endotoxic shock. Molecular and Cellular Biochemistry, 1993, 121, 143-148.	3.1	12